Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.

NCT01838694 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Erythematosus, Systemic

Interventions

BIOLOGICAL: Ala-Cpn10
DRUG: Placebo

Sponsor

Invion, Inc.